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ABSTRACT 
Incidence estimation and calibration from cross-sectional data of acute infection  
HIV-1 seroconvertors. 
 
May 2007 
Eustasius Musenge  
 
Masters in Medicine in the Field of Biostatistics and Epidemiology 
 
Supervised by: Mr E Marinda  and Dr A Welte  
 
Background:  The HIV-1 incidence (a very important measure used as a proxy for 
disease burden) can be estimated from a cross-sectional study. This incidence estimate 
has the advantage of reducing on costs and time, thus enabling more timely 
intervention; it is also ideal for developing nations. A common procedure used in 
making this estimate utilizes two antibody tests (Sensitive/Less sensitive tests). Due to 
the long window period of such tests (at least three months), persons classified as 
recently infected would have been infected more than three months prior to the test 
date. Detecting acute HIV-1 infection is very important since this is the most infectious 
stage of the disease. This research report explores a method of estimating incidence 
using an antibody test and a virological test, Polymerase Chain Reaction Ribonucleic 
Acid (PCR-RNA).The cross-sectional data used are from the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA). 
 
Methods: Actual follow-up cohort data from CAPRISA acute infection cohort (AIC), 
comprised of 245 sex workers, were used to estimate the incidence of HIV-1 using a 
PCR-RNA ,virology test based, incidence formula. The result obtained was compared to 
the incidence estimate obtained by the classical method of estimating incidence 
vii 
(prospective cohort follow-up). As a measure to reduce costs inherent in virological 
tests (PCR-RNA), multistage pooling was discussed and several pooling strategies 
simulations were proposed with their uncertainties. Point estimates and interval 
estimates of the window period, window period prevalence and incidence from cross-
sectional study of the AIC cohort were computed.  
 
Findings: The mean window period was 6.6 days 95% CI: (2.7 – 13.0). The monthly 
window period prevalence was 0.09423 percent 95 % CI: (0.0193 – 0.1865)%. The 
incidence from the prospective cohort follow-up was 5.43 percent  95% CI: (3.9 – 9.2) 
%. The incidence estimate from cross-sectional formulae was 5.21 percent 95% CI: 
(4.1– 4.6). It was also shown by use of simulations that an optimum pool sample size is 
obtained when at least half the samples are removed on every run. 
 
Interpretation and recommendations: The PCR-RNA test is very sensitive at 
detecting acute HIV-1 infected persons. The incidence estimate from the cross- 
sectional study formulae was very similar to that obtained from a follow-up study. The 
number of tests needed can be reduced and a good estimate of the incidence can still be 
obtained. The calibration was not accurate since the samples used were small and the 
window period duration was too short, hence, it was difficult to extrapolate to the whole 
population. Further work still needs to be done on the calibration of the proposed 
incidence formulae as it could be a very useful public health tool. 
viii 
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CHAPTER 1 : INTRODUCTION 
 
1.1 Introduction 
About 922 million people (11 percent of the world’s population) reside in Africa of 
which more than 25 million people are living with HIV/AIDS
1
. More than a fifth (5.5 
million) of these people are from South Africa.
2
 South Africa as a nation has the highest 
absolute number of HIV-infected persons in the world and a prevalence of 30.2%.
3
 The 
nation is divided into nine provinces, one of which is KwaZulu-Natal, which has the 
highest population and HIV prevalence of 39.1% for antenatal attendees. 
Several studies on HIV prevention are underway country-wide including studies 
evaluating the effect of male circumcision on HIV transmission and also studies 
evaluating the impact of microbicide gel use by women on HIV transmission. With 
millions of rands being spent towards HIV-related endeavours, the need for accurate 
statistics and greater understanding of the dynamics of the virus is critical. Prevalence 
(which is the number of cases of a disease that are present in a particular population at a 
given time) and incidence (which is the number of newly diagnosed cases during a 
specific time period) are two very important indicators of disease burden and spread, 
respectively. Another useful measure is the test-specific window period duration, which 
when accurately measured, will enable intervention early after infection (which is the 
most infectious period).
4
 Scientific evidence gathered from South Africa, the region 
with the highest absolute number of HIV-infected persons in the world, will be very 
useful if reliably collected and well validated. 
  2
 
1.2 Statement of the problem and rationale  
Acute HIV infection is the stage of disease progression during which HIV viral 
replication and shedding occur before detectable antibodies occur.
5
 This is also the time 
when the viral load peaks in the blood and genitals,
6
 which is also the most infectious 
period.
3
 Estimation of acute HIV-1 incidence is essential in HIV prevention. The public 
health benefits are that persons with acute HIV infection can be counselled about risk 
reduction behaviours such as abstinence and safer sex to reduce secondary infections.
7
 
This has great benefits such as reduction in transmission to uninfected sexual partners, 
channelling of resources towards this most infectious group and early treatment of the 
acute HIV infected.
8
 
The incidence estimates are important for the purposes of planning vaccine trials and 
disease monitoring and evaluation. The classical method of estimating the incidence 
within a research setting is based upon following an uninfected cohort over time until 
some are infected. This has several limitations, the most common are it is costly, the 
loss to follow-up and also difficulties with respect to distinguishing between those who 
were recently infected (HIV) and those long infected (AIDS). In order to strengthen the 
fight against HIV, there is need to detect places and persons with the highest levels of 
infectiousness in the right time period in order to implement public health interventions. 
A useful epidemiological indicator best suited for this purpose is the acute HIV-1 
incidence. 
  3
 
1.3 Study Objectives 
The aim of this study is to create a calibrating tool useful in estimating HIV incidence 
from recently infected persons in cross-sectional studies. The tool development will 
assess the estimation of the window period (duration between infection and testing 
antibody positive), window period prevalence and incidence estimation. The study will 
provide calibrated combinations of parameters (incidence, window period prevalence 
and window period). The 95% confidence intervals will also be given. The specific 
objectives are: 
1) Estimation of window period for the acute infection cohort. 
2) Computation of incidence from cross-sectional acute infection cohort (AIC) data 
from the Centre for the AIDS Programme of Research in South Africa 
(CAPRISA). 
3) Validation of optimal multistage pooling strategy using data simulations. 
 
1.4 Literature review of methods for measuring incidence 
Prevalence rates which are the most commonly reported statistic for HIV/AIDS include 
full-blown AIDS and recently infected individuals. This may not be very useful in 
tracking the progression of the disease or in providing an instantaneous state of the 
epidemic. Incidence rates which are integral in the design of vaccine efficacy studies, 
calculating sample sizes and allocation interventions are routinely measured from 
prospective follow-up cohort studies.
9
 The following are several ways in which the 
incidence rates are estimated. 
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1.4.1 Observing seroconversions in a prospective follow-up study 
Incidence can be defined as the proportion of seronegative individuals who seroconvert 
during a defined period of observation. Estimating incidence is done by enrolling an 
HIV-negative population in a longitudinal or prospective cohort study and testing the 
participants at regular intervals for new HIV infections, thereby deriving an incidence 
rate (number of new infections per total number of person-years of follow-up).
10
 Also, 
the proportion of positives identified in a cross-sectional study that has markers of 
recent infection is used for estimating incidence.  
1.4.2 Identifying recent seroconverters from a cross-sectional sample using two 
HIV antibody tests of differing sensitivity for HIV antibodies  
This method is described by the Centre for Disease Control (CDC) as the Serological 
Testing Algorithm for Recent HIV Seroconversion (STARHS).
11
 It is also known as the 
“detuned assay” or the “Sensitive Assay/Less Sensitive Assay”. This is a comparison of 
two tests on a single diagnostic specimen. The regular HIV antibody test that is used to 
diagnose HIV infection and a less sensitive version of the same test that only detects 
high levels of HIV antibodies. 
 
The first test indicates whether the person is infected with HIV. If infected, the second, 
less-sensitive test can indicate whether or not the patient has a high level of HIV 
antibodies. Since a person’s level of antibodies gradually increases in the early stages 
after infection, the result of the second test suggests whether they have been infected 
within a shorter (approximately 6 months or less) or longer time. However the 
  5
probability of identifying an infected individual within six months of infection is a 
function of how often they go for testing.
12
 
 
Figure 1-1.  STARHS method to estimate stage of infection using a single diagnostic specimen.
6
 
 
 
The STARHS approach uses the following formula to calculate the annual incidence 
rates (equation 1.2 is the tailor form of equation 1.1): 
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Where R: recent infection (antibody negative), Tw: window period, Nneg: number of HIV 
seronegative. This approach was used by Parekh et al.
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In South Africa, another version of the formula was used in the annual survey for South 
African national HIV incidence, commissioned by the Nelson Mandela Foundation:
2
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is not always possible in these formulae, e.g., when the window period is very small 
(less than 7 days). The assumption made on application of these formulae is that the  
incidence is constant throughout the year preceding the calculation. The formulae are 
globally calibrated to estimate incidence only when antibody-based assays are used to 
identify recently infected HIV-1 persons.
2
  
1.4.3 Inferring incidence from serial cross-sectional surveys 
With this method, incidence is indirectly estimated by the slope of the seroprevalence 
against time, assuming the population being surveyed remains representative over 
time.
14
 
The figure below shows a two-state model of disease within a cohort. At a given age, a, 
x(a) is the number of people without the disease, y(a) is the number of people with the 
disease, i(a) is the incidence rate, and mx(a) and my(a) are the mortality rates among 
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those with and without the disease, and where i is the actual incidence rate based on the 
susceptible population. 
Figure 1-2.  Two state-deterministics model, source
15
 . 
 
 
 
 
 
 
 
The age-specific prevalence of a disease can be obtained from population surveys, 
either by interview or by examination. The mortality of people with the disease can be 
obtained from following up the survey subjects, demographic surveillance surveys or 
from cohort studies.
15
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Where p(a) is the prevalence and N(a)is the total of the susceptible population. 
The estimates of age-specific prevalence are usually ‘noisy’, it is necessary to smooth 
them, taking into account that p(a) must lie between 0 and 1 and, for most diseases, 
increases with age. To reduce the noise a suitable smoothing function is the logistic 
ln[p(a)/{1 - p(a)}]. Figure 1.4 shows the graphs obtained when this approach was used 
for a group of diabetic women in Canada. 
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Figure 1-3. Prevalence and incidence of diabetes in Canadian women, source
16
. 
 
 
 
The graph shows the effect of the smoothing technique and an increase in the estimated 
incidence with increasing age. 
1.4.4 Use of surrogate marker for recent (age specific) infection 
In this approach to estimate HIV incidence, the number of reported AIDS cases in the 
youngest age range of adult cases, ages 13-25, is used as a surrogate for recent trends in 
incidence. The justification for this approach is that the onset of sexual and drug-using 
risk behaviour in the teenage years (or later) leads to the inference of AIDS cases in this 
age group. Predominately those with a short incubation time from infection to AIDS 
reflect relatively recent infections (less than 5 years on average).
17
 Also the AIDS-
related mortality would be less significant in this younger cohort and however the 
incidence among the 18 year olds may differ from that of those in the fifties thus 
generalisability becomes an issue. 
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1.4.5 Back-calculation from reported AIDS cases 
This approach estimates incidence or prevalence by use of a mathematical model called 
‘back calculation’,
 
which combines the available data on the number of reported AIDS 
cases and the incubation period distribution of AIDS (the mathematical function that 
estimates the probability of developing AIDS for each year following HIV infection) to 
derive how many HIV infections occurred during years past.
18
 Back-calculation is done 
by use of the convolution equation: 
dssstFsIta
t
)|()()( −= ∫ ∞− ……………………………………………..Equation 1.6 
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Where a(t) is the expected cumulative number of AIDS cases diagnosed by time t , I(s) 
is the HIV infection rate at time s and F(t|s) is the probability of developing AIDS 
within t years of infection for those who were infected at time s. This approach uses 
information on a(t) and F(t|s) to estimate the infection rate I(s).
19
 
1.4.6 Using capture-recapture methods in serial surveys 
The sixth method is a variant of the cross-sectional survey approach that uses ‘capture-
recapture’, a method long used by biologists to study wildlife populations. It requires a 
unique identifier, of individuals included in repeated surveys, so that the seroconverters 
among those repeatedly tested can be identified.
20
  
1.5 Estimating the window period for HIV primary infection 
The window period is the interval during which an infected individual tests negative to 
an antibody test. Recently infected individuals may however be detected by virological 
  10
assays such as Polymerase Chain Reaction Ribonucleic Acid (PCR-RNA) which also 
has a window period. A procedure known as incidence window period (IWP) is used 
among blood donors. This is derived from an epidemiological relation, 
Prevalence=Incidence x Window period under a steady state assumption on the 
infection dynamics. The IWP estimates the window period by
21
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 Where 0πˆ is the prevalence, Iˆ is the incidence, w  is the average length (duration) of 
HIV window period for the blood bank of interest, N is the total number of repeat 
donors and )( 1)1( ini tt i −+ is time between the donors consecutive donations. 
 
1.6 Optimization of lab work in ‘recent infection’ prevalence studies 
Pooling is a strategy used on biological specimens. Individual serum samples are 
grouped and randomly selected specimens are tested in each group (pool). Based on the 
outcome, the whole pool is classified as positive or negative. Two objectives of pooling 
biological specimens are to identify infected individuals and to estimate the prevalence 
(when it is low) of infection in the population at a lower cost than testing individual 
samples.
22
 When the process is done several times, it is known as multistage pooling.  
In multistage pooling the cohort is divided into equal-numbered pools which are then 
tested. Each positive pool identified in each stage is subdivided to smaller pools in the 
following stage and this is repeated up to the last pool of size one.  
For the multistage pooling study after z stages of pooling algorithm, the incidence rate 
can be estimated by the following relation: 
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Where N is the sample size, S1 is the size of the initial pool sample (thus SZ is the size of 
the z th  pool sample) and N1 the number in the first stage, that is,  N=N1.S1. 
This equation uses concepts discussed by Brookmeyer et al. (2000) in obtaining the 
optimal pooling size. The major aim of pooling blood samples is to identify the number 
of positive infections R in a group of N samples using as few tests as possible (PCR 
runs in the case of the HIV-RNA test). For this to be possible, at least half of the 
samples on every run (stage) must be eliminated and an optimal initial pool size s1. must 
be used (see appendix C). 
 
1.7 Forthcoming discussions 
Having discussed the different approaches of estimating incidence rates, there is still a 
gap to be filled for ideal methods applicable to developing countries and high-risk 
populations in which it is difficult to follow cohorts to identify seroconverters. This 
research report discusses a systematic approach to estimating the incidence and 
calibration, using results from an antibody test (ELISA) and a virological test (PCR-
RNA). The following section discusses the methods employed in the study, design and 
analysis. 
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CHAPTER  2 :  MATERIALS AND METHODS 
2.1 Study design and sample description 
The data which were used for this study were from the Centre for the AIDS Programme 
of Research in South Africa (CAPRISA) in their phase II Acute Infection Cohort (AIC). 
The study design was a prospective observational cohort study conducted at the Doris 
Duke Medical Research Institute (MRI) at the Nelson R. Mandela School of Medicine, 
University of KwaZulu-Natal, Durban, and the CAPRISA Vulindlela Research Facility. 
Study 
participants with acute HIV infection were identified among female sex workers in 
KwaZulu-Natal; from participants in a Phase II/IIb microbicide trial in Durban; and 
from research cohorts in Vulindlela. A diagrammatic illustration of the screening, 
recruitment and enrolment process is shown in Appendix E.
23 
 
A total of 775 participants were assessed from which a cohort of 245 uninfected high-
risk women was selected, where the prevalence among them was greater than 10% or 
incidence greater than 3%. The average age was 34.3 years (range 18-58) and the 
majority (78.8%, n=193) identified themselves as sex-workers. The loss-to-follow-up 
rate was 15.1%.
23 
 The 245 female sex workers were then  assessed monthly between September 2004 and 
July 2006. In this particular study the participants who became HIV infected were 
detected soon after the infection, which made the data suitable for greater in-depth 
observation of early viral and CD4+ T cell bio-dynamics. During the follow-up, two 
  13
tests were administered monthly: a virological test (HIV-RNA PCR) and the sensitive 
antibody test ‘ELISA’. This enabled the estimation of a hypothetical window period, the 
actual duration between the last ELISA negative and first ELISA positive, which has an 
unknown distribution. 
2.2 Testing protocol
 
The two tests administered were an antibody test (ELISA) and a virological test (RNA-
PCR) in individual samples and pools. The ELISA assay assessed for serum binding 
antibodies in blood reacting with purified HIV proteins or peptides from env and gag.
23
 
 
The COBAS AMPLICOR™  HIV-1 MONITOR Test, v1.5 (Standard or the 
Ultrasensitive, Roche Diagnostics) was used to measure viral loads. The test quantifies 
HIV-1 RNA over the range of 50-750 000 copies/ml and has a specificity greater than 
99.85% for quantification of HIV-1 Groups M subtypes A-G. A series of runs was 
performed to ensure reliability and reproducibility including inter-laboratory 
reproducibility.
23 
For detection of HIV-1 RNA in pooled samples, the AMPLISCREENTM HIV-1 Tests 
v1.5 (Roche Diagnostics) were used. A primary pool contained 24 or less samples and 
when found positive, was disaggregated into smaller secondary pools.
23
 
 
2.3  Data analysis concepts 
The incidence estimate from the CAPRISA longitudinal prospective follow-up cohort 
was computed and compared with the incidence estimate from a cross-sectional 
prevalence. Due to the expenses incurred in running PCR-RNA tests on individual 
samples, multistage pooling was used to reduce the number of laboratory tests and 
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costs. Three pooling options will be discussed for the multistage pooling strategy. The 
statistical analysis was done using STATA 9.0 and Excel. The programming of different 
algorithms was carried out using MATLAB. The following section discusses the 
concepts backing the methods utilized for each of the objectives. 
2.3.1 Inference of the window period duration 
The estimation of the PCR-RNA window period was done using the interval between 
the first RNA positive and last RNA negative (which we will call delta ∆), multiplied by 
the probability of seeing an individual in the window period.  
pTw ˆ×∆= …………………………………………………………….Equation 2.1 
Where Tw is the estimate of the window period, ∆ is the average of the interval between 
visits and pˆ is the probability of seeing an individual in the window period. The 
window period can be estimated using either the individual deltas or average delta (as 
shown above). The latter approach is less involved and yields a very similar distribution 
to the former. Mwanga (2006)
24
 obtained the following distributions for the individual 
and the average delta and a window period of 6.8 days. 
Figure 2-1.  Posterior density window period for individual and average delta.
23 
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2.3.2 Modelling of relation between incidence and prevalence of ‘recent infections’ 
In the previous chapter different approaches of estimating the incidence were discussed. 
This section focuses on an approach of estimating incidence from the window period 
prevalence proposed by Mwanga (2006) 
25
, which will be validated in this research 
report. 
Consider an uninfected individual who has had an infectious contact (sexual or other), 
the following stages occur in the prognosis of HIV, namely:  
• Stage 1: infection, this occurs immediately (if contact with infected person was 
infectious).  
• Stage 2: entry into the ‘window state’ (infection is now detectable by a 
virological assay such as PCR-RNA). This occurs at the individual’s own time 
say t1 (which varies) and globally at  say T1 (which is fixed), after infection. In 
fact this test detects acute infection prior to seroconversion. HIV-PCR stands for 
HIV- Polymerase Chain Reaction and is also known as viral load testing because 
it detects the presence of the immuno-deficiency virus in blood  
• Stage 3: exit from the ‘window state’ (infection is now detectable by both 
assays- PCR and ELISA), when antibodies can now be detected. This happens at 
the individual’s time t2 (globally T2) after infection 
The biological distribution of the times t1 and t2 over the population is given by 
),( 21 ttρ which is unknown. Infected individuals can be grouped based on the outcome 
of the two tests as a proxy to indicate how far back from the day of testing they 
contracted the virus, that is t0. 
  16
Figure 2-2.  Schematic illustration of the PCR and ELISA test result.
8 
PCR Negative Positive Positive Negative 
ELISA Negative Negative Positive Positive 
Classification Negative (Nneg) Recently 
Infected ( R) 
Long infected 
(L ) 
Indeterminate 
 
Figure 2-3 below shows how individuals can be classified from a point in time t0=0 on 
the day when they come for testing. There are long-infected (L), recently infected (R) 
and susceptible individuals (Nneg). These classifications are relative to the time from the 
day of testing and when they contracted the HIV, for distant past (long-infected), recent 
past (recently infected) and less than a week (susceptible individuals). 
Figure 2-3. Classification of infected persons at time t0=0. 
 
The “window period” is the time it takes for a person who has been infected with HIV 
to seroconvert (test positive) for HIV antibodies. For simplicity the window period 
Tw=|T2-T1| when individuals enter the window period at a fixed time since infection T1 
and leave at fixed time T2. Hence ),( 21 ttρ , assuming both times to be independent, can 
be written as: 
)()(),( 221121 TtTttt −−= δδρ ……………………………………………...Equation 2.2 
In an infinitesimal cohort the probability of anyone being infected in the window period 
around time t in a period dt is given by: 
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Where max2t is the individual’s maximum time from the test time 0t , when he or she was 
PCR positive and ELISA negative. The time max20 ttt i −= is the earliest time that is 
considered, since all people infected before this time would have left the window period 
by the time they are observed. Consider a gross incidence I from a population ( sN ) 
which gets infected at an incidence rate i. Thus, in a period time dt, the number of new 
cases is given by dtNtidttI s .).()( = for a susceptible population sN . 
The number of persons infected between it and 0t is given by: 
dttNtidttIN
t
t
s
t
t
i
ii
)()()(
00
∫∫ == …………………………………….……..Equation 2.5 
Thus the expected number of persons in the window period is:  
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Since the expected number (Nw) of the recently infected is also given by the 
experimental value R, the above equations can be rewritten in terms of R: 
∫ ∫ ∫
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−−=
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s dtdtdtTtTttNtiR δδ …………….…….Equation 2.8 
In general, the incidence rate of the susceptible population can be modelled by a 
Taylor series, that is : 
+′′+′+= 2/)0()0()0()( 2titiiti ………………………………………..Equation 2.9 
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And:  
.....2/)0()0()0()( 2 +′′+′+= tNtNNtN ……………………………..Equation 2.10  
The incidence was estimated using the formula below whose derivation is discussed in 
appendix A : 
wnegTN
R
i =  …………………………………………………………..Equation 2.11 
Where i is the incidence rate, R the number of recently infected persons, Nneg are the 
susceptible persons and Tw is the window period. This incidence relation can also be 
written, in relation to window period prevalence and window period, where Pw is the 
window period prevalence (i.e., the number of people seen in the window period over 
susceptible Pw=R/Nneg) and Tw is the window period duration estimated from delta (∆), 
the difference between the two dates for RNA negative and positive: 
w
w
T
P
i = ………………………………………………………………….Equation 2.12 
2.3.3 Bayesian estimation 
Bayesian estimation draws inference about unobservable parameters or hypotheses by 
combining two sources of information: 
a) (Prior) beliefs about the parameters formed from past evidence, such as pilot 
studies or similar studies. 
b) Sample data that the study generates.      
The Bayesian approach estimates the probability of the hypothesis H conditional on the 
observed data, i.e., Prob(H | data). This probability is called the posterior. 
Bayes theorem calculates the posterior probability of H as follows: 
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)(
)()|(
)|(
dataP
HPHdataP
dataHP = ……………………………………Equation 2.13 
Where P(data | H) is the likelihood, that is, the probability of observing the data 
conditional on the hypothesis. P(H) is called the prior probability, which is a function 
which quantifies our prior knowledge or beliefs about H. P(data) is the normalizing 
constant, that is, the factor that makes the total probability equal to one.
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2.3.4 Computation of the incidence confidence interval 
Two main procedures were used to compute the confidence intervals for the estimates 
obtained from the data: the Wald interval estimation of binomial proportions and 
Bayesian likelihood estimation. 
 The Wald procedure is an approximate confidence interval estimation of a binomial 
proportion in finite population sampling, computed by: 
1ˆ
)ˆ1(ˆ
1ˆ%100)1(
2 +
−
−±=×−
n
pp
fzpCIWald αα ……………………Equation 2.14 
Where p is the prevalence, f is the sample fraction and 2 2ˆ αznn += . This procedure was 
used in estimating the confidence interval of the ‘window period prevalence’, which 
was done using STATA 9.0.  
The Bayesian likelihood  procedure was used to estimate the incidence confidence 
interval. The likelihood function of obtaining the number of recent infections for a 
particular incidence with an associated window period is given as: 
∫
∫
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><><⋅><
=
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www
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iRL
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)(), |(
)|( …………………Equation 2.15 
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Where )| ()( ><=>< ww tdatadcallibrateLtprob . L is the likelihood and R are the 
recently infected. 
The denominator in equation 2.15 is for normalizing the likelihood. This procedure was 
performed in Excel by making use of small discrete intervals of time. It was used to 
estimate the confidence interval for the ‘window period’ as well as that for the 
‘incidence’. The procedure did not require any distributional assumptions of any 
distribution. The Bayesian approach also has the advantage of providing an the required 
estimate  and interval band(credibility interval), distribution (posterior) and graphical 
output. 
2.3.5 Multistage pooling incidence rate 
For the multistage pooling study after, e.g., z stages of pooling algorithm, the incidence 
rate will be estimated by the following relation after replacing Pw with pˆ  from equation 
B6 in appendix B. 
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………………………………………………….Equation 2.16
 24 
The error introduced by lack of sensitivity and specificity is known.
26
 The selection of 
the initial pool size is integral to the effect of minimizing the impact of false positives 
and false negatives.  
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2.3.6 Optimal pooling strategy  
The major aim of pooling blood samples is to identify the number of positive infections 
R in a group of N samples using as few tests as possible (PCR runs in the case of HIV-
RNA test). For this to be possible, at least half of the samples on every run (stage) needs 
to be eliminated (PCR runs in the case of HIV-RNA test), and optimal initial pool size 
s1 must be used. 
fpp
s
2ln
)1ln(
2ln
)1ln(
2ln
1 =−
=
−
−
=   ………………………………………..……………Equation 2.17
 8 
The equation 2.17 derived in appendix C gives the optimal initial pool size where, f is 
the expected frequency of individual being in the window period. When, p = 1-ε (very 
high prevalence) where ε is a small nonnegative number, individual testing is 
preferable. 
The true value for disease prevalence (p) is not known in advance, and poor choice of p 
may lead to an imprecise estimate of initial pool size. The multistage pooling study 
allows one to adapt the pool size. This is done by observing the cost (variance) of 
reducing or adding of the pool size after each pooling stage. In practice, adapting the 
pool size after each stage is not pleasant and clinicians prefer having the pooling 
algorithm before starting to run the PCR in order to reduce time wastage. It has been  
observed that once one has a good estimate of the initial pool, positive pools that are 
broken into sub-pools of half the size provide an optimal pooling algorithm. 
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2.4 Ethical Clearance 
The study was granted ethical clearance from three universities including the University 
of the Witwatersrand, clearance number MM040202. The research report received 
ethical clearance from the University of the Witwatersrand, clearance number W-CJ-
070504-1. 
 
CHAPTER 3 : RESULTS 
 
3.1 Incidence from direct follow-up 
Two hundred and forty-five sex workers were followed up and 19 seroconverted 
observed in 350 person years (127 353 person-days). This yields an incidence of 5.43% 
per year with a 95 % confidence interval of  (3.9 - 9.2) % per year. 
3.2 The results of systematic estimation of incidence 
Table 3.1 below shows the interval between observations delta (∆), which is calculated 
by differencing the last PCR negative and first PCR positive. A participant was 
observed in the window period if the PCR status switched from negative to positive and 
antibody negative on the same day as the first PCR positive. The data had a total of 21 
participants who seroconverted and of these 2 did not have any follow-up information, 
and were thus removed from the analysis. The results show that out of the 19 persons 
who seroconverted, 4 of them were seen in the window period. 
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Table 3.1.  Seroconvertors and those seen in the window period. 
Participant 
id 
∆ 
(in days) 
seen in 
window 
100136 23 No 
100040 26 No 
100200 27 No 
100239 28 No 
100174 28 No 
100225 28 No 
100137 28 No 
100222 28 No 
100069 28 Yes 
100221 28 Yes 
100177 28 Yes 
100229 29 No 
100065 29 No 
100037 29 No 
100129 33 No 
100045 34 Yes 
100008 35 No 
100085 53 No 
100206 55 No 
Mean ∆ 31.42105      
 
The probability of seeing an individual in the window period was 4/19 and this was 
used to fit different models to estimate the likelihood probability of finding a 
seroconverter in the window period, namely Binomial and Poisson. The following were 
the corresponding probabilities together with their respective confidence intervals. 
Table 3.2. Fitted likelihood functions. 
Model Likelihood L Standard 
Error 
Confidence Interval (95%) 
Binomial 0.2105263     0.0935288         (0.0605245   ,   0.4556531) 
Poisson 0.2105263     0.1052632         (0.0573613   ,  0.539031) 
The window period is estimated by using the delta function, the likelihood function and 
the following: 
• Four participants were observed in the window period. 
  24
• There were 21 infections (seroconversions) of which 19 had enough information 
for the computation of the interval (∆) between consecutive observation times. 
• The average interval (∆) between observation times is 31.42 days. 
Thus yearsdaysTw 0181.061496.62105263.042105.31 ≈=×=  days with a 95% 
confidence interval of (1.90–14.32) days assuming a binomial likelihood using the 
Wald’s approximation. This was also computed directly (exact) using the cumulative  
95% confidence intervals and linear interpolation techniques yielding (2.69 – 13.01)%, 
which is narrower. The latter approach was more preferred than the former since the 
normal approximation is not ideal for expected mean less than 5 (in this instance mean 
np=4). 
Figure 3-1. Bayesian posterior likelihood for ‘window period’. 
posterior
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The figure above gives the posterior likelihood function for the window period of 6.6 
days with a 95% confidence interval of (2.69 – 13.01) days using Excel. 
 
3.3  Incidence and mean window period prevalence estimation 
The window period prevalence was computed using: 
neg
w
N
R
P =  
From the four people seen in the window period over the 4245 person-months (350 
person-years), the window period prevalence estimate is 0.09423 % and a 95% 
confidence interval of (0.0193 – 0.1865)% using the Wald’s confidence interval 
approximation for finite populations. 
This yields an incidence: %21.5
0181.0
09423.0
==i  using the equation: 
 
w
w
T
P
i = …………………………………………………….. Equation 2.12. 
This has a 95% confidence interval of (4.144 – 14.564)%. 
3.4  Example of ‘ideal’ pooling strategy versus ‘practical’ pooling strategy 
The available data were not sufficient to test for the optimum pooling strategy, since 
this required a large sample to be divided into different pools. Mwanga (2006)
 25 
discussed  three pooling algorithms. The first has pool size of (100; 50; 10; 1), which 
was used in detection of acute HIV-1 infection in North Carolina
27
 and in South 
Africa.
28
 The second (Strategy 2) was computed with a prevalence p = 0.0109 and 
halving the positive pools at each stage pooling algorithm with pool a size of (64; 32; 
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16; 8; 4; 2; 1). The last pooling algorithm (25; 5; 1), given as strategy 3, is proposed as a 
practical pooling strategy proposed by local experts. 
Incidence estimates using the three pooling algorithms are shown in table 3.3 where iˆ  
is the estimate of incidence using a multistage pooling procedure (equation 2.16) and i  
is the exact incidence from prospective cohort follow-up. In various studies 
20, 21
 as well 
as the simulations in this study, the window period duration was 28 days which was 
made from a sample of size N=6400. 
 
Table 3.3.  Incidence estimates using three pooling algorithms. 
Strategy 
1. Pool size 100 50 10 1 
 iˆ % per year 8.67 8.61 8.56 8.56 
 610ˆ)( −×− ii  14.22 0.54 7.69 0 
2. Pool size 64 32 16 8 4 2 1 
 iˆ % per year 8.62 8.58 8.57 8.56 8.56 8.56 8.56 
 610ˆ)( −×− ii  8.46 19.72 8.95 0.2 1.71 0.57 0 
3. Pool size 25 5 1 
 iˆ % per year 8.57 8.56 8.56 
 610ˆ)( −×− ii  8.8 2.29 0 
 
Table 3.3 above shows by use of simulations that an optimum pool sample size is 
obtained when at least half of the samples are eliminated at every run. The results also 
show that in screening a large population using a multistage pooling algorithm for the 
purpose of estimating HIV incidence, it is not necessary to stop at pools of size one. 
Strategy 2 shows it suffices to stop at the pools of size 8, which will still give a good 
approximation of the incidence. Similarly, strategies 1 and 3 show that one can stop at 
the pools of size 10 and 5, respectively, and still produce a robust estimate of incidence. 
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Thus, applying a multistage pooling algorithm for estimating HIV incidence rate has the 
potential of dramatically reducing the cost of testing. 
 
3.5  Summary of results 
The mean window period was 6.6 days 95% CI: (2.7 – 13.0). The monthly window 
period prevalence was 0.09423 % 95 % CI: (0.0193 – 0.1865)%. The incidence from 
direct follow-up was 5.43 percent 95% CI: (3.9 – 9.2 )%. The incidence estimate from 
cross-sectional formulae was 5.21 percent 95% CI: (4.1 – 14.6 ). The cross-sectional 
incidence is about 4.05% lower than that obtained by direct follow-up of the cohort. It 
was also shown by use of simulations that an optimum pool sample size is obtained 
when at least half of the samples are eliminated at every run. The simulated data also 
showed that multistage pooling has great potential of reducing the cost of estimating 
incidence in a cross-sectional study. 
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CHAPTER 4 
CONCLUSIONS, LIMITATIONS & PROPOSAL FOR FURTHER WORK 
Epidemiological principles that govern a quality programme for accurate and 
representative prevalence estimates also apply to cross-sectional incident infections. 
These include the selection of the appropriate target population, the validation of it 
being representative, the identification of any selection, accrual or testing bias that may 
distort the representation, as well as programmatic issues such as enrolment, specimen 
handling, transport, testing, data management and quality assurance.
29
 
 
The estimation of incidence is the result of a calculation requiring three measurements: 
the number classified as incident; the window period; and the number of seronegative 
(at-risk) members of the population.
29
 The accuracy of the estimate is thus dependent on 
the accuracy of all three measurements. 
 
The window period for the HIV-PCR in this study was found to be 6.6 days for 
sensitivity of at least 50copies/ml. Fiebig et al. (2003) proposed six stages of primary 
(acute) HIV-1 infection with regards to blood samples being detected by RNA, p24 
antigen, enzyme immunoassays (EIA) and the Western Blot. Table 4.1 shows the results 
obtained together with the 95% confidence intervals. 
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Table 4.1. Laboratory stages of primary HIV infection, source
 30
. 
Stage RNA p24-
Antigen 
EIA -
not 
sensitive 
EIA -
sensitive 
Western 
Blot 
Duration in days 
(95% CI) 
I + - - - - 5.0 (3.1 , 8.1) 
II + + - - - 5.3 (3.7 , 7.7) 
III + + - + - 3.2 (2.1 , 4.8) 
IV + +/- - + | 5.6 (3.8 , 8.1) 
V + +/- +/- + + 69.5 (39.7 , 121.7) 
VI + +/- + + + Open ended 
 
This study showed that the PCR-RNA test was very sensitive and yielded a very similar 
result to that obtained with the lab results in table 4.1. The window period of 6.6 days 
95% CI: (2.69 – 13.01) is similar to the window period obtained from the same cohort a 
year before, i.e., 6.8 days 95% CI: (3 – 13). The latter yielded better point and incident 
estimates since more persons were tested (23, including others from other studies) 
compared to this year’s 19 (AIC only). The table also shows that HIV-RNA testing may 
still increase the sensitivity for HIV detection. It is also a worthwhile addition to HIV 
prevention efforts and useful in identifying persons with acute HIV infection, which 
should remain a public health priority. Hence the sensitivity also shows that the use of 
HIV RNA testing can readily identify persons with acute HIV infection (who are the 
most infectious and more likely to transmit the virus)
3
 and other acute sexually 
transmitted infections. It may be more useful to use a longer window period by detuning 
the antibody assay, in order to mimic the real life situation more practically. 
 
There are also issues regarding the sample size estimation (McDougal et al. 2005). If 
the prevalence (P) is known, the total population size needed is Nneg = (no. at risk)/(1 - 
P). A Sensitive/Less sensitive assay with a 150-day window period and an anticipated 
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incidence of 5% would require that 4642, 1168 or 519 seronegative specimens accrue 
throughout the follow-up to achieve a ±1%, 2%, or 3% CI, respectively. An assay with 
a 10-fold shorter window period, such as the viral assays, would require 10-fold higher 
numbers.
29 
 
The monthly window period prevalence for the study was found to be 0.09423 % and 
the 95% CI: (0.0193 – 0.1865)%, which is comparable to that found a year before 
0.15% and 95% CI: (0.06 – 0.34) %. The incidence from direct follow-up was 5.43 
percent 95% CI: (3.9 – 9.2)% .The incidence estimate from cross-sectional formulae 
was 5.21 percent 95% CI: (4.1 – 14.6 ). This interval is wider and other procedures such 
as Bootstrap estimations may also be used in further studies. 
  
It was also shown by use of simulations that an optimum pool sample size is obtained 
when at least half the samples are eliminated at every run. In screening a large 
population using a multistage pooling algorithm for the purpose of estimating HIV 
incidence, it is not mandatory to stop at pools of size one. Strategy 2 shows it suffices to 
stop at the pools of size 8, which will still give a good approximation of the incidence. 
Similarly, strategies 1 and 3 show that one can stop at the pools of size 10 and 5, 
respectively, and still produce a robust estimate of incidence. Thus, applying a 
multistage pooling algorithm for estimating HIV incidence rate can dramatically reduce 
the cost of testing. 
For the multistage pooling strategy, it was shown that an optimal pooling algorithm can 
be achieved by halving the pool size at each stage of executing the pooling algorithm. 
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This was done using strategy 2, yet this runs more tests until one pool is left. This 
showed less error (obtained by use of the mean and standard deviation of PCR runs) 
compared to the other two strategies (see appendix D). Where E[Npositive] is the 
expected number of positive specimens in the sample of 6400 specimens. Multistage 
pooling when used to run the PCR test in combination with a very sensitive assay can 
reduce the cost of estimating the incidence remarkably and the number of tests by over 
75% compared to p24 antigen testing.
31
 
In general, the issues surrounding the generalization or extrapolation of results from a 
sentinel population to the larger epidemic are the same for prevalence and incidence 
data. A unique feature of incidence that is relevant to extrapolation is a point estimate, 
whereas prevalence reflects cumulative experience with HIV-1. Prevalence reasonably 
reflects HIV-1 exposure before, during and after pregnancy for antenatal clinic data. 
Incidence reflects recent exposure shortly before or during pregnancy in the case of 
antenatal attendees. If there is a difference in risky behaviour and incidence before and 
during pregnancy, the extrapolation to non-pregnant women of the same age may not be 
valid.
29 
A more informative incidence estimate, a pooled estimate based on estimates from 
different provinces, may be more useful to generalize the incidence to the whole 
population. The actual number of persons in the window period is also very low and 
large data may need to be used to validate the formulae. The PCR-RNA test is very 
sensitive at detecting acute HIV-1 infected persons. The incidence estimate from the 
cross-sectional study formulae was very similar to that obtained from a follow-up study. 
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The number of tests needed can be reduced and a good estimate of the incidence can 
still be calculated. The calibration was not accurate since the samples used were small 
and the window period duration too short, hence it was difficult to extrapolate to the 
whole population. Further work still has to be done on the calibration of these incidence 
formulae as it can serve as a very useful public health tool.
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APPENDIX A: DERIVATION FOR ACUTE HIV-1 FORMULAE  
This is the derivation of an incidence for cross-sectional studies based on results 
obtained from and antibody test (ELISA) and virological test (RNA-PCR). This formula 
was proposed by Mwanga (2006) 
25
. 
If a linearly decreasing closed population (at rateλ ) is considered, the number 
susceptible can be written as:  
tNNtN sss λ)0()0()( −=  ………………………………………………..Equation A1 
At time t0, when participants appear for testing. Shifting the reference point to the date 
of the first PCR positive test, that is, time –t1, the susceptible population can be given as 
ttNtNtN sss λ)()()( 11 −−−=   and replacing λλ )( 1tN s −=′ : 
ttNtN ss λ ′−−= )()( 1 ……………………………..……………………...Equation A2 
Then the number of recently infected R (section 2.3.2) is given by: 
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Assuming a constant yearly incidence, that is, i(t) = i. 
    





′+−=
2
)(
2
1
w
ws
T
TtNiR λ …..……………………………………..…Equation A5 
Replacing )( 1tN s − with negN : 
)
2
(
/
wneg
w
TN
TR
i
λ ′
+
= …………………………………………………...Equation A6 
1
2
1
−







 ′
+= w
negwneg
T
NTN
R
i
λ
………………………………..……..…Equation A7 
  34
Series expansion of equation: 
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Assuming the population does not vary much over time, hence keeping only the first 
order term we obtain: 
wnegTN
R
i = ……………………………………………………………….Equation 2.11 
APPENDIX B : MULTISTAGE POOLING INCIDENCE  
In a one-stage pooling study, if there is a sample of N seronegative specimens (for HIV-
RNA test), the sample can be divided into n1 pools of size s1, thus N=n1.s1 given x1 of 
these pools are positive and y1 are negative such that n1 = x1+y1. In order to 
systematically determine the probability p that a person has the disease without error 
(assuming perfect sensitivity and specificity of the test), the maximum likelihood 
estimate (MLE) must be determined. The individual tests can be taken as Bernoulli 
trials, thus the likelihood would be a binomial distribution. 
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Finding the natural logarithm of both sides. 
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Thus after some algebra, this yields the MLE of p: 
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For large n1 the variance of the MLE of p is estimated by 
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This is only applicable to the one stage pooling case, but one pooling is usually not 
sufficient, thus, there is a need for multistage pooling. It can similarly be shown that p 
yields a good estimate for a multistage study pooling study, which is the generalization 
of a single stage pooling study. 
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And the corresponding estimate of the variance.
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In order to estimate the incidence from cross-sectional prevalence, it should be assumed 
that R individuals in the sample of N seronegative individuals are found to be recently 
HIV infected. If the mean window period duration (Tw) of these individuals is known: 
NT
R
T
P
i
ww
w == …………………………………………………………..Equation 2.11 
Where Pw=R/N is the proportion of  individuals seen in the window period namely the 
window period prevalence. 
For the multistage pooling study after, e.g., z stages of pooling algorithm, the incidence 
rate will be estimated by the following relation after replacing Pw with pˆ from equation 
B6. 
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The error introduced by lack of sensitivity and specificity is known.
24
 The selection of 
the initial pool size is integral to the effect of minimizing the effect of false positives 
and false negatives.  
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APPENDIX C : DERIVATION OPTIMAL POOLING STRATEGY 
If there is a sample of N specimens that is pooled into np pools of size s1 (s1 being the 
initial pool size) and p is the prevalence of infected individuals in this sample, then the 
probability that in this pool of size s1 there are exactly k infected individuals can be 
modelled by the binomial distribution. 
ksk
pp
k
s
kXP
−−





== 11 )1()( 1 ……………………….………………..Equation C1 
Where, X is a random variable and k ≤ R. Thus, the probability of a pool testing positive 
is P[X ≥1], i.e., at least one individual in the pool has infection. This can be written as: 
P(at least 1 positive) = 1- P(none positive) i.e. )0(1)1(1)1( =−=<−=≥ XPXPXP  
1)1(1)1( spXP −−=≥  
To minimize the number of PCR runs, at least half of the initial pools should test 
negative. If 
1)1(
2
1
)0(
s
pXP −===  and making s1the subject, the following equation is obtained: 
f
In
pIn
In
pIn
In
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2
)1(
2
)1(
2
1 =−
=
−
−
=   ………………………………………..……………Equation 2.17 
8 
Equation 2.17 gives the optimal initial pool size where f is the expected frequency of 
individual being in the window period. When  p = 1-ε (very high prevalence),  where ε 
is a small nonnegative number, individual testing is preferable. 
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